Complete financial analysis of Cara Therapeutics, Inc. (CARA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cara Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Mega Lifesciences Public Company Limited (MEGA.BK) Income Statement Analysis – Financial Results
- Software Aktiengesellschaft (SOW.DE) Income Statement Analysis – Financial Results
- Teco Image Systems Co., Ltd. (5438.TWO) Income Statement Analysis – Financial Results
- TPK Holding Co., Ltd. (3673.TW) Income Statement Analysis – Financial Results
- Chart Industries, Inc. (GTLS-PB) Income Statement Analysis – Financial Results
Cara Therapeutics, Inc. (CARA)
About Cara Therapeutics, Inc.
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20.97M | 41.87M | 23.03M | 135.08M | 19.89M | 13.47M | 911.00K | 86.00K | 3.80M | 3.18M | 11.96M | 1.19M | 0.00 |
| Cost of Revenue | 6.17M | 7.27M | 1.55M | 107.07M | 113.16M | 75.53M | 48.52M | 49.25M | 21.22M | 15.07M | 8.69M | 1.92M | 0.00 |
| Gross Profit | 14.79M | 34.60M | 21.47M | 28.01M | -93.28M | -62.06M | -47.61M | -49.17M | -17.42M | -11.89M | 3.28M | -731.00K | 0.00 |
| Gross Profit Ratio | 70.56% | 82.65% | 93.25% | 20.74% | -469.06% | -460.78% | -5,226.45% | -57,170.93% | -458.01% | -374.28% | 27.41% | -61.43% | 0.00% |
| Research & Development | 108.51M | 91.88M | 82.70M | 107.85M | 113.82M | 75.53M | 48.52M | 49.25M | 21.22M | 15.07M | 8.69M | 4.60M | 7.16M |
| General & Administrative | 27.65M | 30.26M | 29.41M | 21.75M | 17.75M | 15.32M | 11.87M | 9.23M | 7.77M | 6.18M | 3.52M | 2.83M | 2.41M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 27.65M | 30.26M | 29.41M | 21.75M | 17.75M | 15.32M | 11.87M | 9.23M | 7.77M | 6.18M | 3.52M | 2.83M | 2.41M |
| Other Expenses | 0.00 | 2.06M | 642.00K | 97.00K | 4.49M | 2.98M | 1.16M | 652.00K | 101.00K | 361.00K | 0.00 | 0.00 | -180.00K |
| Operating Expenses | 136.29M | 122.14M | 112.11M | 129.70M | 131.57M | 90.85M | 60.40M | 58.49M | 28.99M | 21.25M | 12.20M | 7.43M | 9.57M |
| Cost & Expenses | 142.46M | 129.40M | 112.11M | 129.70M | 131.57M | 90.85M | 60.40M | 58.49M | 28.99M | 21.25M | 12.20M | 7.43M | 9.57M |
| Interest Income | 0.00 | 2.06M | 603.00K | 2.06M | 4.49M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 604.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 126.00K | 3.76M | 0.00 | 0.00 |
| Depreciation & Amortization | 259.00K | 1.67M | 1.55M | 1.01M | 799.00K | 370.00K | 495.00K | 1.47M | 839.00K | 783.00K | 789.00K | 1.02M | 1.17M |
| EBITDA | -117.65M | -83.80M | -88.19M | 5.59M | -111.48M | -77.01M | -58.99M | -56.94M | -24.35M | -17.29M | 552.00K | -5.22M | -8.58M |
| EBITDA Ratio | -561.09% | -209.08% | -386.85% | 4.14% | -561.60% | -574.52% | -6,529.64% | -67,906.98% | -662.32% | -568.84% | -1.98% | -438.24% | 0.00% |
| Operating Income | -121.50M | -87.54M | -89.08M | 5.39M | -111.68M | -77.38M | -59.49M | -58.40M | -25.19M | -18.07M | -237.00K | -6.24M | -9.57M |
| Operating Income Ratio | -579.43% | -209.08% | -386.85% | 3.99% | -561.60% | -574.52% | -6,529.64% | -67,906.98% | -662.32% | -568.84% | -1.98% | -524.03% | 0.00% |
| Total Other Income/Expenses | 2.98M | 2.06M | 642.00K | 2.33M | 4.49M | 2.98M | 1.16M | 652.00K | 101.00K | 126.00K | -3.76M | -66.00K | -275.00K |
| Income Before Tax | -118.51M | -85.47M | -88.44M | 7.72M | -107.19M | -74.40M | -58.33M | -57.75M | -25.09M | -17.95M | -3.99M | -6.30M | -9.84M |
| Income Before Tax Ratio | -565.21% | -204.16% | -384.06% | 5.71% | -539.02% | -552.39% | -6,402.74% | -67,148.84% | -659.66% | -564.87% | -33.38% | -529.58% | 0.00% |
| Income Tax Expense | 0.00 | -2.06M | -248.00K | -691.00K | -816.00K | -389.00K | -204.00K | -468.00K | -397.00K | -201.00K | -30.00K | -31.00K | -35.00K |
| Net Income | -118.51M | -83.41M | -88.19M | 8.41M | -106.37M | -74.01M | -58.13M | -57.28M | -24.69M | -17.75M | -3.96M | -6.27M | -9.81M |
| Net Income Ratio | -565.21% | -199.23% | -382.98% | 6.23% | -534.91% | -549.51% | -6,380.35% | -66,604.65% | -649.22% | -558.55% | -33.12% | -526.97% | 0.00% |
| EPS | -2.19 | -1.55 | -1.74 | 0.18 | -2.49 | -2.06 | -1.86 | -2.10 | -1.00 | -0.85 | -0.18 | -1.01 | -1.59 |
| EPS Diluted | -2.19 | -1.55 | -1.74 | 0.18 | -2.49 | -2.06 | -1.86 | -2.10 | -1.00 | -0.85 | -0.18 | -1.01 | -1.59 |
| Weighted Avg Shares Out | 54.15M | 53.65M | 50.72M | 47.41M | 42.67M | 35.89M | 31.20M | 27.28M | 24.62M | 20.88M | 21.84M | 6.18M | 6.18M |
| Weighted Avg Shares Out (Dil) | 54.15M | 53.65M | 50.72M | 47.92M | 42.67M | 35.89M | 31.20M | 27.28M | 24.62M | 20.97M | 21.84M | 6.18M | 6.18M |
Is Cara Therapeutics Stock a Buy After Its First FDA Drug Approval
Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates
Why Cara Therapeutics Shot Higher Today
CARA Stock: The Huge FDA News Sending Cara Therapeutics Skyrocketing Today
Biotech Stock Takes on Technical Ceiling After FDA Okay
CARA Drug Wins FDA Nod for Pruritus Associated With CKD
Why Is Cara Therapeutics Stock Trading Higher Today?
See Why Cara Therapeutics (CARA) Stock Is Moving Higher On Tuesday
Cara Therapeutics Shares Increase Over 20% Pre-Market: Why It Happened
Vifor Pharma and Cara Therapeutics announce U.S. FDA approval of KORSUVA™ injection for the treatment of moderate-to-severe pruritus in hemodialysis patients
Source: https://incomestatements.info
Category: Stock Reports